and buying on dips is " FOR ME" the right strategy for a company with huge potential and a realistic chance to succeed.
Only for folks who like to go for the BIG ONE, so BIG that they only need ONE.
is the fact how fast results from SYN-004 will be available. SYN has turned into one of my most interesting Biotech with NO CONCERNS about dilution as long as the science holds up to its promise.
Actually it is kind of huge in this setting, Dr. Langer pulls a lot of weight. So the PR effect can be called huge.
FOR YEARS, even before I invested in NVIV , I got convinced by statements of leading scientists and studies that cells grow better when they have some kind of support and are not subject to a violent hostile environment.
The scaffold alone is a start, but with the clear potential of a major game changer. Those who want to put a price on a game changer with short term considerations will most likely miss the boat when the game changer is suddenly considered a fact. And Dr. Langer has the reputation to create just that.
His upcoming presentation carries a lot of weight.
For patient Nr 4 and 5 to arrive and Dr. Langers presentation.
If you can smell $$$$$$ give it a thump up :-) :-)
If you cannot smell $$$$$ give it a thump down
That the upcoming presentation of Dr. Langer can be considered HUGE.
He will not be talking about some potential cancer cure, he will be talking about a device, a device which works. He can hold it up like a stent and you know how much money they make on those stents.
GAME CHANGER FOR THE SPINE
I am not a trader, but I can tell that you have no clue what's ahead for the company, also not that hard to tell that the MO MO is up.
Jesi is a sweetheart. She says it as she sees it . Optimistic, brave just all around an inspiration. Now that's a girl who belongs in real TV and not all those other weirdos.
Spine injuries have left patients paralyzed for such a log time and the world understands this huge problem.
NVIV is on its way to get HUGE recognition. Say welcome to big money trying to get part of this game changer.
I not even wanted to look at my portfolio this morning, expecting big Greece pain. And then I saw the NVIV gain and read the spectacular news.
This for sure made my day.
To go after the highest bidder for their C. difficult infection science. But I think the company will go it alone.
Just too much potential in it to share. Maybe in regards to future distribution a big partner would be of value, but it will not be cheap to get part of the action.
The key issue is how you use the ATM machine. Without ANY question , wisely used and used to strike a deal with the financing at hand, is great. We have to trust the company and if you do not trust the company , it is better to sell your shares.
Your thoughts about a Pfizer partnership makes incredible sense to me. One of the best intelligence assessments I have read so far. Seen as a coming strategy, planned for quite some time, it explains a lot in regards to delays, and at the end a blockbuster combination.